Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss

MLA

Dahu Qi, et al. “Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.” Frontiers in Pharmacology, vol. 11, Jan. 2021. EBSCOhost, https://doi.org/10.3389/fphar.2020.621110.

APA

Dahu Qi, Hui Liu, Xuying Sun, Danni Luo, Meipeng Zhu, Tenghui Tao, Chenghao Gao, Chuankun Zhou, Wei Zhou, & Jun Xiao. (2021). Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.621110

Chicago

Dahu Qi, Hui Liu, Xuying Sun, Danni Luo, Meipeng Zhu, Tenghui Tao, Chenghao Gao, Chuankun Zhou, Wei Zhou, and Jun Xiao. 2021. “Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.” Frontiers in Pharmacology 11 (January). doi:10.3389/fphar.2020.621110.